Eine Kamera ist auf eine reflektierende Glasscheibe gerichtet.
© DZIF

News

All current DZIF news can be found here.

The picture shows a large group of people in a modern lecture hall. Many of the participants are wearing name tags on blue ribbons. In the foreground, there is a sign that reads “Welcome! DZIF Annual Meeting 2023”.
© U. Pucknat | info@pucknas.pictures

Focus on infection research: Press invitation to the Joint Annual Meeting of DGI and DZIF, February 13-15 in Munich

More than 400 experts from the German Center for Infection Research (DZIF) and the German Society for Infectious Diseases (DGI) will meet in Munich from February 13-15, 2025 for their Joint Annual

DZIF Spendenaktion &Julia
© DZIF

17,000 times thank you!

In December 2024, Hamburg-based live entertainment company Stage Entertainment launched a fundraising campaign as part of the pop musical “& Julia”. The aim of the campaign was to raise funds for HIV

Electron micrograph of a hepatitis C virus particle.
© Center for the Study of Hepatitis C, The Rockefeller University/via Wikimedia Commons

A major step for HCV research

The only natural host of the hepatitis C virus (HCV) is humans. Model organisms for laboratory studies, especially mice, cannot be infected which makes the search for a vaccine against HCV extremely

Yellow-orange virus particles in the middle of blue-stained cell tissue
© NIAID/NIH

Faster response to new virus variants

Viruses are masters at disguise. When they are pushed too far by our immune system, they send new virus variants into play that are no longer recognized by immune cells. They escape our immune system

The picture shows the legs of several people who are visibly affected by severe swelling. At the top left, there is a stylised sun symbol, next to which is the text ‘World NTD Day’. The picture is a reference to World Day for Neglected Tropical Diseases.
© Jubin Osei‐Mensah / KCCR Ghana

World Neglected Tropical Diseases Day 2025 on 30 January

The World Health Organization (WHO) estimates that more than 1.5 billion people are affected by neglected tropical diseases (NTDs) and a further two billion are threatened by these diseases. If left

Red-coloured rod-shaped bacteria in an electron micrograph.
© CDC/Alissa Eckert; James Archer

Tuberculosis research: promising new active agent

Tuberculosis is the most common infectious disease worldwide. In 2022 alone, there were 10.6 million new infections and 1.3 million deaths. The European-African network PanACEA—a consortium of

Coronaviren als Bedrohung
© Tumisu auf Pixabay

Horizon Europe project DEFENDER: New targets for antiviral therapies

The interdisciplinary project DEFENDER is developing innovative approaches to combat (re-)emerging viruses. The project, coordinated by the Leibniz Institute of Virology (LIV), is being funded with

Members of the round table dialogue, from left: Georg Kippels (MdB), Thomas Müller (BMG), Helge Braun (MdB), Marc Gitzinger (BEAM Alliance), Thomas Hälbig (GKV-Spitzenverband), and Timo Jäger (DZIF)
© DNAMR

Second working meeting of the Parliamentary Group against Antimicrobial Resistance

Antimicrobial resistance (AMR) is one of the greatest challenges for global health and development. According to estimates by the World Health Organisation (WHO), almost five million deaths worldwide

The EBViously logo is depicted on a washed-out background with bluish cells and green-coloured EBV particles.
© CDC/Dr. Paul M Feorino/EBViously/DZIF

Start-up EBViously founded

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV)

Three agar plates with Streptomyces colonies in different colours (reddish, blue, orange).
© HIPS/Fu

Activating the hidden pharmaceutical potential of bacteria

Microorganisms produce a wide variety of natural products that can be used as active agents to treat diseases such as infections or cancer. The blueprints for these molecules can be found in the